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Abbreviations 
CFT  clot formation time 
CP  cryoprecipitate 
CT  clotting time 
CV  coefficient of variation 
EX-TEM proprietary tissue factor activated assay 
FFP  fresh frozen plasma 
FFP + CP fresh frozen plasma with admixed cryoprecipitate 
ICC  intraclass correlation coefficient 
IN-TEM proprietary ellagic acid activated assay 
K time  clot formation time 
MA  maximum amplitude 
MCF  maximum clot firmness 
PRP  platelet-rich plasma 
R time  reaction time 
ROTEM thromboelastometry 
TEG  thromboelastography 
TF  tissue factor 
 
Abstract 
Objective – To establish and compare the repeatability and reproducibility of activated 
thromboelastography (TEG) and thromboelastometry (ROTEM) assays. 
Design – Multicenter in vitro test standardization. 
Setting – Veterinary academic centers. 
Animals – Test samples were obtained from normal, healthy dogs. Sixty, identical 5 mL aliquots 
of canine platelet-rich plasma collected by apheresis, frozen in 6% dimethyl sulfoxide were 
tested initially. Sixty, identical 6 mL aliquots of canine fresh-frozen plasma with admixed 
cryoprecipitate were subsequently evaluated. 
Interventions – None. 
Measurements and Main Results – Frozen study samples, quality controls, reagents, and 
consumables were distributed to participating centers (7 TEG, 3 ROTEM). Thromboelastography 
centers analyzed study samples with kaolin and tissue factor activated assays; ROTEM centers 
ran proprietary ellagic acid activated and tissue factor activated assays. All machines underwent 
quality control prior to sample analysis. Within- and between-center coefficients of variation 
(CVs) were calculated and compared by Mann-Whitney tests and calculation of intraclass 
correlation coefficients. Within and between centers, individual parameters for both TEG and 
ROTEM assays were comparable. Both within-center and between-center CVs varied markedly 
(0.7 – 120.5% and 1.4 – 116.5%, respectively) with assay type, instrument, and parameter. 
Coefficients of variation for equivalent parameters were not significantly different between the 2 
platforms. Intraclass correlation coefficients suggested moderate agreement between centers. In 
general, individual parameter CVs for platelet-rich plasma samples were lower in TEG centers, 
while CVs for canine fresh-frozen plasma with admixed cryoprecipitate samples were lower in 
ROTEM centers.  
Conclusions – More variation within and between centers was identified than anticipated, but 
some parameters such as alpha angle were repeatable and reproducible. Sample types for future 
multicenter standardization efforts will require further optimization and may need to be adapted 
separately to each platform. Individual centers using viscoelastic tests for evaluation and 
management of clinical patients should take steps to minimize pre-analytical and analytical 
sources of variation. 
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Introduction 
Patients with bleeding diatheses and thromboembolic disorders are frequently encountered in 
veterinary emergency and critical care practice. Optimizing the management of these animals 
requires identification of the cause and severity of their coagulation disorder, which may be 
multifactorial in origin. Ex vivo rotational viscoelastic tests of coagulation, namely 
thromboelastography (TEG) and thromboelastometry (ROTEM), provide a global assessment of 
hemostasis that integrates both the cellular and plasma components of the hemostatic system,1 
which may enhance understanding of the nature2 and severity3 of the coagulation disturbances 
seen in veterinary patients.4 The TEG and ROTEM analysis systems employ a similar test 
principle and provide comparable, although not identical, results.5,6 These tests are proposed to 
better reflect the cell-based model of hemostasis,7 which may enable assessment of hemorrhage 
risk in the clinical setting better than routine plasma based assays.3,8 Such monitoring is now 
recommended in select human perioperative scenarios.9 
Within the veterinary TEG / ROTEM literature, various modifications of the basic assay 
have been employed and evaluated. Differences exist in 3 particular areas: control of pre-
analytical variables such as anticoagulant type or blood collection system,10,11 the method used to 
activate clot formation,12 and modifications of the assay to enhance evaluation of specific 
hemostatic system components.13-15 Previous work has highlighted the potential variation in data 
that can result from small changes in pre-analytical variables,16 and through use of different 
activators.17 It is likely that some of these differences are sufficient to alter interpretation of data 
obtained within the same clinical laboratory, which may lead to inappropriate diagnosis or 
alterations in patient management. In addition, variation between the assays used at different 
centers limits the comparability of published results, which limits the utility and impact of the 
veterinary TEG literature and hampers progress. As has been recently recognized in human 
medicine, standardization of TEG is a priority for the field.18,19 To address this, the Partnership 
for ROtational ViscoElastic Test Standardization (PROVETS) collaboration was established 
from an international group of veterinary clinicians and investigators,20 and was based on a 
similar project undertaken in human medicine.21 The PROVETS collaboration devised evidence-
based guidelines for assay performance and reporting,22-27 in an attempt to improve consistency 
in assay conduct, interpretation, and reporting between centers. 
Currently there is very little information on inter-assay variation in TEG in veterinary 
medicine. Experimental evaluation of assay reproducibility is fundamental to assay 
standardization and is essential for fair comparison of data obtained from different centers.28 
Assay comparability is required in order that data generated in 1 center can be used to diagnose 
and treat patients appropriately in other centers,29 and so that research efforts conducted in 
different centers can collectively move the field forward. The process of evaluating coagulation 
assay comparability is challenging, however, since obtaining and distributing standardized test 
material for hemostasis assays is difficult.30 To achieve worldwide distribution typically requires 
the use of lyophilized or frozen material,21 despite the fact that most hemostasis laboratories 
analyze whole blood or fresh plasma samples. 
The PROVETS group sought to determine the comparability of the results obtained by 
different TEG centers and secondarily, whether results obtained from similar TEG and ROTEM 
assays were comparable. Specifically, our objectives were: to establish the intra- and inter-assay 
coefficients of variation (CVs) for the contact pathway and the tissue factor activated assays on 
the TEG and ROTEM platforms, and to compare the repeatability and reproducibility of both 
contact pathway and tissue factor activated assays on both platforms within and between centers. 
Based on the literature, it was hypothesized that CVs between centers would be significantly 
greater than those within centers for all assays;21 that CVs of assays using different activators 
would not be significantly different within centers;31 and that CVs for equivalent TEG and 
ROTEM assays would not be significantly different.32 
 
Materials and Methods 
Participating centers 
Ten centers across 7 countries in North America and Europe were chosen from the PROVETS 
collaborating institutions based on their willingness and ability to perform sample evaluation, 
their access to suitable numbers of test machines and their demonstrated expertise in the field. 
These centers (alphabetized by country) were: University of Calgary, Calgary, Canada (TEG); 
University of Copenhagen, Frederiksberg, Denmark (TEG); VetAgro Sup, Lyon, France 
(ROTEM); University of Turin, Turin, Italy (ROTEM); University of Zurich, Zurich, 
Switzerland (ROTEM); Royal Veterinary College, London, UK (TEG), Cornell University, 
Ithaca, NY (TEG); University of California, Davis, CA (TEG); University of Georgia, Athens, 
GA (TEG); Tufts University, Grafton, MA (TEG). 
 
Test material 
Two sets of samples were obtained and distributed to participating centers. Sample choice for the 
first iteration was modeled on a similar study in human medicine.21 In the first iteration, 60 
custom-made, identical 5 mL aliquots of canine platelet-rich plasma (PRP) collected by 
apheresis from a single canine platelet donor were obtained from a commercial veterinary blood 
bank.a At collection, the PRP had a platelet count of 700,000 cells/µL. Prior to freezing, 6% 
dimethylsulfoxide was added to the samples, which were then frozen at -80°C and sent to the 
coordinating center overnight on dry ice. These samples were maintained at -80°C prior to 
distribution to participating centers. The 60 samples were divided into groups of 5 aliquots of 5 
mL each. These batches of samples were sent from the organizing location to each participating 
center on dry ice by express courier. Each center was notified in advance to expect the 
shipments. Each center assessed the samples to determine whether they were still completely 
frozen upon arrival. Upon receipt these samples were stored at -80°C until analysis. Samples 
were distributed to participating centers in April 2014 and all analyses were completed within 4 
months of sample receipt at all participating centers. 
In the second iteration, attempts were made to overcome limitations present in the 
samples from the first round of analyses. Platelets were eliminated from the test material and in 
an attempt to ensure clot formation time (K-time or CFT) would be consistently measurable, 
plasma samples with admixed cryoprecipitate were generated. To produce these custom samples, 
480 mL of canine fresh frozen plasma (FFP; 2 x 240 mL units) and 210 mL of lyophilized canine 
cryoprecipitate (3 x 70 mL units) were obtained from the same commercial veterinary blood 
bank. Acid-citrate-dextrose-adenine was used as the anticoagulant for preparation of both FFP 
and cryoprecipitate. The FFP was thawed to room temperature and the cryoprecipitate 
reconstituted over 10 minutes at room temperature using FFP as the diluent. The resulting 
solution was aseptically filtered using a 100 µm filter,b to remove particulates and aggregates. 
Samples of FFP and the resulting plasma/cryoprecipitate mixture (FFP + CP) were collected and 
their fibrinogen concentrations measured by the Clauss method by use of a human thrombin 
reagent,c and a standard curve was derived from dilutions of a canine plasma standard.d The 
plasma/cryoprecipitate solution was then aliquoted into 6 mL aliquots in 15 mL conical bottom 
polypropylene tubes,e and frozen at -80°C, prior to shipping to participating centers as previously 
described for the PRP samples. The second set of samples were distributed to participating 
centers in February 2015 and all analyses were completed within 4 months of sample receipt at 
the participating centers. 
 
Consumables 
To ensure uniformity in reagent and plasticware batches, all study consumables were purchased 
by the organizing center, divided into center-specific consignments and then distributed to the 
participating locations. The (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid with bovine 
serum albumin (HEPES-BSA) buffer (2% BSA, 20 mM HEPES, 150 mM NaCl) required for the 
tissue factor (TF) assay on the TEG platform was made up at the organizing center as previously 
described.33,f,g This solution was aliquoted in 15 mL conical bottom tubes and frozen at -80°C 
prior to shipping to TEG centers. Where additional preparatory steps that could only be 
performed locally were required, detailed instructions were supplied to each participating center 
to ensure solutions are produced correctly and to maximize uniformity (see supplemental data). 
 
Analyzers 
All instruments underwent maintenance checks within 30 days of analyzing study samples. For 
TEG, Level 1 and Level 2 quality control samplesh were evaluated prior to analysis of study 
samples. Internal electronic quality control tests were conducted on all TEG machines prior to 
study sample testing. Sites with ROTEM analyzers ran ROTROL-N and ROTROL-P controlsi to 
verify instrument performance prior to analyzing study samples. 
 
Assays 
At each center, a single operator analyzed all samples according to a specific study protocol 
distributed to each center with the consumables (see supplemental data). If multiple TEG 
machines were available, then any number of channels could be used simultaneously, provided 
each channel successfully passed both electronic and quality control tests. No ROTEM center 
had > 1 analyzer, thus a maximum of 4 channels were used for simultaneous ROTEM analyses. 
For both TEG and ROTEM a contact pathway activated assay (kaolin for TEG, proprietary 
ellagic acid activated assay [IN-TEM] for ROTEM) and tissue factor activated assay (non-
proprietary for TEG, proprietary tissue factor activated assay [EX-TEM] for ROTEM) were 
performed. Manual pipetting was performed for TEG assays. Electronic pipetting was performed 
for ROTEM assays. Repeats were performed consecutively until plasma sample aliquots were 
used up or 2 hours had lapsed since samples were thawed. Fresh aliquots were thawed as 
necessary to complete the required replicates. Relevant in-built analysis software was used to 
calculate values for 4 TEG variables: reaction time (R-time), K-time, clot formation angle (alpha 
angle) and maximum amplitude (MA); and 4 ROTEM variables: clotting time (CT), CFT, clot 
formation angle (alpha angle) and maximum clot firmness (MCF). Each test was run for 60 
minutes or until MA/MCF was reached. Twenty repeats per assay were performed.23 All assays 
were run at 37°C. 
For TEG, aliquots of test plasma were recalcified with 0.2M CaCl2 reagent at the time of 
analysis,j with calcium chloride being added to pre-warmed TEG cups prior to addition of the 
test sample. Proprietary kaolin-activated assays were performed as previously described.12,k To 
evaluate extrinsic pathway activation by TF, a solution of recombinant human TF with synthetic 
phospholipid,l in HEPES-BSA was used. In the first iteration, a final concentration of 1:50,000 
was used per Wiinberg et al. 2005,33 while in the second iteration a higher TF final concentration 
of 1:3,600 was used to increase the likelihood that the MA/MCF reached 20 mm. For ROTEM, 
aliquots of test plasma were recalcified using a proprietary 0.2M CaCl2 in HEPES product,
m with 
mixing using automatic pipette as recommended by the manufacturer. Contact pathway 
activation on the ROTEM platform was performed using a proprietary ellagic acid reagent,n 
while a proprietary recombinant TF and phospholipid product,o was used to activate the extrinsic 
pathway.16 
 
Statistical analyses 
Data were assessed for normality using the D'Agostino–Pearson test.p Within-center CVs were 
calculated for each of the key TEG/ROTEM variables for each of the analysis types using the 
following equation: CV = SD / Mean. Comparisons of CVs between TEG centers and separately 
between ROTEM centers were performed using 2-way ANOVA. In these analyses, the column 
factor was defined as center, the row factor defined as the assay parameter (R-time, K-time, 
alpha angle, MA for TEG; CT, CFT, alpha angle and MCF for ROTEM). Coefficients of 
variation for the individual parameters were compared between analysis platforms using Mann–
Whitney tests, with Bonferroni’s correction for multiple comparisons. Between center CVs were 
calculated from the mean values derived for each variable from each center. Cronbach’s alpha 
(C-α) and intraclass correlation coefficients (ICC) for absolute agreement using a 2-way mixed 
effects model were calculated to evaluate the degree of correlation between the values from the 7 
TEG centers and from the values from the 3 ROTEM centers. Data were sorted in ascending 
value prior to calculation of C-α and the ICC values.q Values for C-α ≥ 0.9 were considered to 
represent excellent consistency, 0.7 ≤ C-α < 0.9 good consistency, 0.6 ≤ C-α < 0.7 acceptable 
consistency, 0.5 ≤ C-α < 0.6 poor consistency and < 0.5 unacceptable consistency.34 Values for 
ICC values > 0.8 were considered to indicate near-perfect agreement, 0.7 – 0.8 strong agreement, 
0.5 – 0.7 moderate agreement, 0.3 – 0.5 fair agreement, and < 0.3 poor agreement.35 
 
Results 
PRP-samples 
For the first iteration of the study, data were available from 9 of the 10 centers including 6 TEG 
centers and 3 ROTEM centers. Data from many of the TEG and ROTEM variables were 
normally distributed, but some were not, hence the data are summarized in the figures by 
median, interquartile range, minimum-maximum. For the calculation of CVs, means and SDs 
were still calculated in order to use this established metric of assay variance. The distributions of 
the CVs were also non-parametric and hence were compared with Mann–Whitney tests. Samples 
sent to 1 of the TEG centers (Center 2) thawed en route and although the assays were conducted, 
the resulting data were not used for analysis. 
Values for the individual tracing variables within the TEG centers for the 2 different TEG 
assays are shown in Figure 1. Within the TEG centers, some parameters were more variable than 
others; CVs from the 20 repeated assays at each center are presented in Table 1. Within the TEG 
centers, the variables with the lowest CVs were alpha angle and MA for both kaolin and TF 
activated assays. Visual inspection of box and whisker plots suggests that in most centers R-time 
and K-time also had low variability, although their lower mean values produced high CVs. 
Between TEG centers, the variables with the lowest CVs were alpha angle for kaolin-
activated assays, and alpha angle and R-time for TF-activated assays (Table 2). There was no 
significant difference between the CVs for any of the TEG parameters for either the TF or kaolin 
activated assays, P = 0.336 and P = 0.124, respectively. Analysis of the C-α and ICC indices 
suggests that for both TF and kaolin assays, the R time and the MA had the highest consistency 
values, while R time had the highest ICC values suggestive of moderate agreement between TEG 
centers. Overall, the C-α values for the TEG assays using PRP samples varied between 0.30 – 
0.95, while the ICC values varied between 0.15 – 0.65. 
Values for the individual tracing variables within the ROTEM centers for the 2 different 
ROTEM assays are shown in Figure 2. The low MCF values precluded complete assessment of 
the CFT. Within the ROTEM centers, alpha angle had the lowest CVs for both the IN-TEM and 
EX-TEM assays. 
Between ROTEM centers, the variables with the lowest CVs were CT and alpha angle for 
both IN-TEM and EX-TEM assays (Table 3). There was no significant difference between the 
CVs for any of the ROTEM parameters for either the EX-TEM or IN-TEM assays, P = 0.425 and 
P = 0.414, respectively. Analysis of the C-α and ICC indices suggests that for both IN-TEM and 
EX-TEM assays, the MCF had the highest consistency values, while CT had the highest ICC 
values. Overall, the C-α values for the ROTEM assays using PRP samples varied between 0.49 – 
0.96, while the ICC values varied between 0.05 – 0.78. 
 
FFP + CP samples 
The pooled FFP used for the reconstitution of the cryoprecipitate had a fibrinogen concentration 
of 5.20 µmol/L [177 mg/dL]. After addition of the cryoprecipitate, the FFP + CP samples created 
for the second iteration of the study had a fibrinogen concentration of 10.85 µmol/L [369 
mg/dL]. For this part of the study, data were available from all 10 centers (7 TEG, 3 ROTEM). 
Within and between TEG centers, values for the individual variables for the 2 different TEG 
assays were more variable than was the case with the PRP samples (Figure 3). Within TEG 
centers, the MA values in the kaolin-activated assays and the R-time values in the TF assays had 
the lowest CVs. Between TEG center CVs were higher for most variables than was the case for 
the PRP samples, with the exception of MA, which was less variable with the FFP + CP samples 
than with the PRP samples. There was no significant difference between the CVs for any of the 
TEG parameters for either the TF or kaolin activated assays, P = 0.631 and P = 0.417 
respectively. Overall, the C-α values for the TEG assays using FFP + CP samples varied between 
0.56 – 0.97, while the ICC values varied between 0.37 – 0.76. 
The analyses of the FFP + CP samples within and between ROTEM centers were less 
variable (Figure 4, Table 4). Within individual ROTEM centers, alpha angle and MCF had the 
lowest CVs for IN-TEM assays, while CT, alpha angle, and MCF all had low CVs with the EX-
TEM assay. Between ROTEM centers, the variables with the lowest CVs were alpha angle and 
MCF for both IN-TEM and EX-TEM assays. There was no significant difference between the 
CVs for any of the ROTEM parameters for either the EX-TEM or IN-TEM assays, P = 0.932 and 
P = 0.566, respectively. Analysis of the C-α and ICC indices suggests that for IN-TEM assays, 
the CT and alpha angle values were the most consistent and had the highest agreement between 
centers. For the EX-TEM assays, the MCF had the highest consistency and between-center 
agreement values. Overall, the C-α values for the ROTEM assays using FFP + CP samples 
varied between 0.26 – 0.97, while the ICC values varied between 0.19 – 0.96. 
 
Variation in TEG assays compared to ROTEM assays  
To test the hypothesis that the variability of equivalent TEG and ROTEM assays are not 
significantly different, we compared the CVs for the TEG assays to the CVs for the ROTEM 
assays. None of the CVs for the individual TEG variables (R time, K time, alpha angle, MA) 
were significantly different from the CVs for the corresponding individual ROTEM variables 
(CT, CFT, alpha angle, MCF) at P < 0.05, after adjustment for multiple comparisons. 
 
Discussion 
This study aimed to establish intra- and inter-assay CVs for contact pathway and TF-activated 
assays on both the TEG and ROTEM platforms; and to compare the repeatability (within center) 
and reproducibility (between center) of these assays within and between centers. Overall, the 
results suggest that the degree of variability both within and between centers was unacceptably 
high (CVs frequently > 10%).21 The centers concurred on the measurement of the TEG/ROTEM 
parameters to variable extents depending on the parameter assessed with some individual assays 
in some centers being highly repeatable (kaolin TEG with PRP and FFP + CP, IN-TEM and EX-
TEM with FFP + CP), while others were much less consistent. It should be noted that there is 
little agreement on what constitutes acceptable within-center or between-center CVs for 
coagulation assays.36 Since the CV is numerically dependent on the mean value, a 10% CV for 
MA might represent a standard deviation of ± 6mm if the mean is 60mm. Such a difference 
might affect interpretation. In contrast, a 10% CV for R time where the mean value is 2 minutes 
represents a SD of ± 0.2 minutes, which might not affect interpretation of R time. As such, the 
variation in each parameter may need to be interpreted individually. 
The C-α parameter is a measure of internal consistency, that is, how closely related a set 
of items are as a group,37 and is typically interpreted as a measure of reliability, where 1 
represents perfect consistency between assay parameters. Based on this metric alone, most TEG 
and ROTEM parameters had good consistency between centers (exceptions were the K time for 
TEG and the CFT for ROTEM assays). This finding suggests the same assays in different 
locations are measuring similar aspects of the coagulation process. The lack of consistency with 
K time and CFT values may be due primarily to a number of tracings had an MA or MCF only 
just above 20 mm, inconsistently prolonging these clot formation time parameters. 
The ICC represents the level of agreement between the centers and accounts for both 
inter- and intra-center variability or alternatively, an index for the reliability of different centers 
averaged together.34 In general, the ICC values indicated fair to moderate agreement at best for 
the various parameters among TEG centers. For the ROTEM centers, particularly with FFP + CP 
samples, the calculated ICC values suggest strong agreement for IN-TEM CT and alpha angle 
and EX-TEM MCF, and fair or poor agreement for the remainder. This is consistent with the 
distributions apparent from Figures 2 and 4. It should be recognized that we had fewer ROTEM 
centers than TEG centers, which may have increased the variation seen between TEG centers. 
There are various potential analytical and pre-analytical sources of the variation observed 
here.38 We attempted to minimize sources of error we could control, including the analyzers, 
assay consumables, machine operators, and the samples. It is probable that viscoelastic 
coagulation testing and the hemostatic process ex vivo are inherently variable to some extent. 
There are likely to be differences between analysis platforms and assays that also contributed to 
variability. For instance, the TF assay for TEG is non-proprietary and requires user preparation, 
in contrast to the EX-TEM assay for the ROTEM platform, which is standardized by the 
manufacturer. The TEG system uses manual pipetting, while the ROTEM platform incorporates 
an automatic pipette. 
Despite our efforts to minimize biologic variation, the source we consider most likely to 
be the cause of the variation is the nature of the samples tested. In order to assess the 
repeatability and reproducibility within and between centers, every center tested identical 
samples. To accomplish this on a worldwide scale, use of plasma-based samples was required 
since whole blood samples would have degraded in transit. The multicenter nature of the project 
necessitated samples that would not be altered by the freeze-thaw process required to send 
identical aliquots of a clinically relevant biologic material to collaborators in 7 countries. 
Previous work suggests that canine plasma is sufficiently stable when frozen, such that any 
impact on hemostatic analyses is minimal.39,40 Use of plasma samples also allowed for analysis 
of multiple samples in a single run, minimizing between-run variation. The original intention 
was to provide centers with lyophilized plasma, since this sample type was used in human 
external quality assessments of TEG.29,41 Ultimately, however, lyophilized canine plasma could 
not be obtained from a commercial animal blood bank. We therefore opted to use frozen plasma 
samples. While these samples were more readily available, they were more challenging and 
costly to ship. 
The first iteration of this project generated promising data from multiple centers, 
established the logistics for the multicenter international collaboration, and confirmed the 
potential of this approach. From these analyses, it appeared that the CVs from some assays and 
from some centers were acceptably low and that in many cases the results were similar. It was 
also clear that the variation in some centers was unacceptably high, however. Based on feedback 
from the test centers, much of this variability was inherent in the test samples since in some 
centers clots were visible in some of the samples, likely due to activation of platelets within the 
PRP and consequent aggregation. Based on these observations, the standardized test material was 
further refined. The presence of the platelets in the samples likely increased clot strength through 
their physical integration into the forming clot and by providing additional phosphatidylserine 
expressing surfaces for the assembly of coagulation factor complexes thereby accelerating clot 
formation.42 It is likely that few of the platelets survived the freeze/thaw process despite the 
presence of the dimethylsulfoxide.43,44 At the time of collection, our PRP samples contained a 
high number of platelets in an attempt to account for the anticipated loss due to the freeze/thaw 
process. The anecdotally reported pre-clotted samples that some centers received suggest that 
some platelet activation occurred during sample preparation. To avoid this in the second 
iteration, platelets were eliminated from the samples. The removal of platelets from the samples 
may have had unanticipated consequences. Removal of the platelet derived phospholipid may 
have reduced the surface area available for coagulation factor complex assembly, thus affecting 
the assays. The TF reagent used in the extrinsic TEG assay contains some synthetic 
phospholipids and so to offset the elimination of the platelets, we increased the final TF reagent 
concentration in the TEG assays during the second part of the study. 
For the second iteration of this study, we considered various alternative sample types. 
One potential alternative option was to use the lyophilized quality control materials supplied by 
the analyzer manufacturers. The study by Chitlur and others in 201121 reported reproducibility 
data from the College of American Pathologists that suggested excellent reproducibility across a 
large number of centers is possible for TEG using this type of lyophilized plasma sample. 
Although using lyophyilized plasma may have improved our consistency, the relevance of this 
approach to veterinary medicine was felt to be questionable since these quality control materials 
are not derived from canine, feline, or equine proteins. Fresh frozen plasma samples alone were 
not considered suitable. Typically, canine plasma-only TEG tracings have maximum amplitudes 
< 20 mm and hence do not enable measurement of K time on the TEG or CFT on the ROTEM 
platform.39 Previous work suggested that a minimum fibrinogen concentration of 8.8 µmol/L 
[300 mg/dL] in the final sample is necessary to generate MCF of > 20 mm.45 No commercial 
source of canine fibrinogen was available to enable production of hyperfibrinogenemic samples, 
and thus canine FFP + CP samples were produced to enhance the fibrinogen concentrations.46 
While these samples eliminated the platelet associated problems encountered in the first part of 
the study, they occasionally produced TEG and ROTEM tracings with MA / MCF values < 20 
mm, and hence K time / CFT values were not universally available. Specific differences in the 
design of the analyzers may also contribute to differences in sensitivity. In the TEG assay, the 
cup rotates while the pin is stationary, while in ROTEM the pin is rotated within a stationary 
cup. These subtle differences might alter the torque generated within the system using platelet-
poor samples. Future work in this field will require further optimization of sample types. Our 
results suggest that optimization of a PRP-based sample type would enhance standardization of 
the TEG platform, since CVs were generally better for this sample type on the TEG platform, 
while FFP + CP based samples may be better suited to standardization of the ROTEM platform. 
Despite the challenges we experienced, our results are comparable to those of the similar 
effort to standardize TEG and ROTEM assays in human medicine.21 In that study, PRP, pooled 
plasma from healthy individuals, and factor VIII deficient plasma samples were evaluated on 
both TEG and ROTEM analyzers in multiple countries. That study reported CVs ranging from 
3.12% – 59.98% depending on the combination of sample type, assay, parameter, and platform. 
The authors identified that significant between-center variation was present (CVs > 10%), but 
also concluded that this was in part due to sample type. 
A recent human study compared the repeatability and reproducibility of TEG and 
ROTEM assays using whole blood collected from patients undergoing elective cardiac surgery.47 
Contact pathway assays (kaolin and IN-TEM) were performed and inter- and intra-operator CVs 
calculated. That study found that both inter- and intra-operator CVs were significantly lower for 
ROTEM assays than for TEG assays. Our study differed in design, being multicenter rather than 
single center and also analyzed plasma-based samples rather than whole blood. Our study 
demonstrated that the within-center CVs from the TEG centers were generally lower than those 
for ROTEM using the PRP samples, while the within-center CVs from the ROTEM centers were 
generally lower than those for the TEG centers using the FFP + CP samples. Given the finding 
with the PRP samples, this may be related solely to the sample type, but there may also be lower 
variability in the proprietary ROTEM EX-TEM assay compared with the user defined TF assay 
used for TEG. After adjustment for multiple comparisons (n = 15), none of the differences 
between CVs for the 2 platforms were significant, however. 
The use of plasma samples does raise the important question of clinical relevance, since 
these assays are designed to analyze whole blood. Our aim was to determine assay repeatability 
and reproducibility, and our data suggest that the degree of variability observed was too high. 
Reassuringly, data from a human multicenter study determining whole-blood reference ranges 
for ROTEM suggests that CVs under 15% are feasible.48 Worldwide standardization of TEG and 
ROTEM using whole blood cannot be achieved. However, it might be feasible to run whole 
blood samples in laboratories in separate centers in 1 geographic area, as was recently achieved 
in human medicine.49 For veterinary medicine, this might be feasible where multiple TEG 
equipped centers exist, such as in a major metropolitan area. 
Until such additional studies are undertaken, we can only recommend that individual 
centers take all possible steps to reduce variation within their own analyses, and that they 
scrutinize the data from other centers to ensure assays were meticulously performed. It is clear 
that the assays are sensitive to small degrees of analytic and biologic variation. The ability to 
discern subtle abnormalities is a potential strength, but clearly is also a potential weakness if 
suitable care and attention are not paid to sample collection, preparation, handling, and analysis. 
We therefore encourage users of viscoelastic tests to use the evidence-based guidelines 
developed for these assays22 to minimize sources of variation and thereby maximize the 
diagnostic utility of these methods. 
   
Footnotes 
a Animal Blood Resources International, Stockbridge, MI 
b Falcon Cell Strainer 100µm, BD Biosciences, Bedford, MA 
c Fibrinogen (100 U/mL), Diagnostica Stago, Parsippany, NJ 
d Cornell Comparative Coagulation Laboratory, Ithaca, NY 
e Falcon Conical Tubes, BD Biosciences, Bedford, MA 
f N-(2-Hydroxyethyl)piperazine-N-2-ethanesulfonic acid, Fisher Scientific, Waltham, MA 
g Bovine serum albumin, Fisher Scientific, Waltham, MA 
h Level I and Level II Controls, Hemonetics, Braintree, MA 
i ROTROL N and ROTROL P, Tem Systems, Inc., Durham, NC 
j Calcium chloride, Hemonetics, Braintree, MA 
k Kaolin, Hemonetics, Braintree, MA 
l Innovin, Siemens Medical Solutions USA, Malvern, PA 
m STAR-TEM, TEM Systems, Inc., Durham, NC 
n EX-TEM, TEM Systems, Inc., Durham, NC 
o IN-TEM, TEM Systems, Inc., Durham, NC  
p Prism 6.0, GraphPad Software Inc., La Jolla, CA 
q IBM SPSS Statistics v21.0, IBM Corp., Armonk, NY 
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Figures 
  
Figure 1 
Box and whisker plots representing the median, interquartile range, and minimum-maximum 
values for the 4 principal TEG variables: R time, K time, alpha angle, and MA. Data were 
generated in 7 centers in 4 countries using platelet-rich plasma samples. Panels A – D represent 
data from the proprietary kaolin-activated TEG assay, which evaluates contact pathway 
activation, while panels E – H represent data from a tissue factor pathway activated assay. This 
assay, as previously reported,33 uses recombinant human tissue factor (1:50,000 final dilution) to 
activate coagulation via the extrinsic pathway. 
 
Alpha (), alpha angle / clot formation angle; K time, clot formation time; MA, maximum 
amplitude; min, minutes; R time, reaction time; TEG, thromboelastography 
 
  
Figure 2 
Box and whisker plots representing the median, interquartile range and minimum-maximum 
values for the 4 principal ROTEM variables: CT, CFT, clot formation angle (alpha angle) and 
MCF. Data were generated from 3 centers in 3 countries using PRP samples. Panels A – D 
represent data from the IN-TEM, which evaluates contact pathway activation, while panels E – H 
represent data from the EX-TEM.  
Alpha (), alpha angle; CFT, clot-formation time; CT, clotting time; EX-TEM, proprietary 
tissue-factor assay; IN-TEM, proprietary ellagic acid activated assay; MCF, maximum clot 
firmness; min, minutes; PRP, platelet-rich plasma; ROTEM, thromboelastometry 
 
 
  
Figure 3 
Box and whisker plots representing the median, interquartile range and minimum-maximum 
values for the 4 principal TEG variables: R time, K time, alpha angle, and MA. Data were 
generated in 7 centers in 4 countries using FFP samples with augmented fibrinogen 
concentrations. Panels A – D represent data from the proprietary kaolin-activated TEG assay that 
evaluates contact pathway activation, while panels E – H represent data from a customized tissue 
factor pathway activated assay. This assay also used recombinant human tissue factor to activate 
coagulation via the extrinsic pathway, but employed a lesser dilution (1:3,600 final TF 
concentration). Alpha (), alpha angle / clot formation angle; FFP, fresh-frozen plasma; K time, 
clot formation time; MA, maximum amplitude; min, minutes; R time, reaction time; TEG, 
thromboelastography; TF, tissue factor 
 
 
  
Figure 4 
Box and whisker plots representing the median, interquartile range and minimum-maximum 
values for the 4 principal ROTEM variables: CT, CFT, alpha angle, and MCF. Data were 
generated in 3 centers in 3 countries using fresh-frozen plasma samples with augmented 
fibrinogen concentrations. Panels A – D represent data from the proprietary celite-activated 
assay (IN-TEM) which evaluates contact pathway activation, while panels E – H represent data 
from the proprietary tissue-factor assay (EX-TEM). Alpha (), alpha angle; CFT, clot formation 
time; CT, clotting time; EX-TEM, proprietary tissue-factor assay; IN-TEM, proprietary ellagic 
acid activated assay; MCF, maximum clot firmness; min, minutes; PRP, platelet-rich plasma; 
ROTEM, thromboelastometry. 
 
 
 
 
Tables 
Table 1. Within-center CVs for TEG assays (%), rounded to the nearest whole number. For the 
PRP analyses, data for Center 2 were not analyzed because the samples thawed in transit.  
C1 – C7, Center 1 to Center 7; CVs, coefficients of variation; FFP + CP, fresh frozen plasma 
with admixed cryoprecipitate; K time, clot formation time; MA, maximum amplitude; PRP, 
platelet-rich plasma; R time, reaction time; TEG, thromboelastography; TF, tissue factor. 
  PRP FFP + CP 
Test Parameter C1 C2 C3 C4 C5 C6 C7 C1 C2 C3 C4 C5 C6 C7 
Kaolin R time 24  12 20 6 31 14 22 7 20 30 13 10 23 
K time 23  12 12 14 73 18 73 36 37 57 43 27 66 
Alpha angle 3  1 1 3 12 3 11 8 17 31 18 8 30 
MA 8  5 4 13 20 3 5 4 5 20 7 6 16 
TF R time 9  9 28 8 8 9 14 14 23 53 16 18 23 
K time 11  8 14 77 36 8 44 - - 89 31 61 66 
Alpha angle 3  2 4 26 19 2 28 29 28 75 18 38 30 
MA 8  4 8 34 16 3 13 18 22 69 19 23 16 
 
 
Table 2. Summary TEG assay data and between-center CVs for TEG assays (%). Coefficients of 
variation have been rounded to the nearest whole number. For the PRP analyses, data for Center 
2 were not analyzed because the samples thawed in transit.  
C-α, Cronbach’s alpha; CVs, coefficients of variation; FFP + CP, fresh frozen plasma with 
admixed cryoprecipitate; ICC, intraclass correlation coefficient; K time, clot formation time; 
MA, maximum amplitude; min, minutes; PRP, platelet-rich plasma; R time, reaction time; TEG, 
thromboelastography; TF, tissue factor. 
  
PRP FFP + CP 
Test Parameter Mean SD CV (%) C-α ICC Mean SD CV (%) C-α ICC 
Kaolin R time (min) 2.4 0.7 31 0.94 0.60 8.0 2.3 29 0.85 0.50 
K time (min) 2.0 2.3 117 0.30 0.15 3.3 1.5 47 0.79 0.60 
Alpha angle (°) 75.0 4.2 6 0.84 0.58 56.3 9.5 17 0.96 0.76 
MA (mm) 55.9 10.6 19 0.94 0.47 24.1 2.4 10 0.85 0.56 
TF R time (min) 2.9 0.5 17 0.95 0.65 4.7 1.3 27 0.81 0.47 
K time (min) 2.4 1.9 80 0.45 0.28 6.1 2.7 45 0.56 0.37 
Alpha angle (°) 65.9 12.6 19 0.77 0.33 37.0 14.5 39 0.93 0.53 
MA (mm) 50.5 15.4 31 0.93 0.31 18.6 4.7 25 0.97 0.57 
 
 
 
  
Table 3. Summary ROTEM assay data and between-center CV for ROTEM assays (%). 
Coefficients of variation have been rounded to the nearest whole number. Some tracings failed to 
reach MCF > 20mm and hence values for CFT for some assays were not available. Coefficients 
of variation could not be calculated for these assays, indicated by (-). 
C-α, Cronbach’s alpha; CFT, clot formation time; CT, clotting time; CV, coefficients of 
variation; EX-TEM, proprietary tissue factors activated assay; FFP + CP, fresh frozen plasma 
with admixed cryoprecipitate; ICC, intraclass correlation coefficient; IN-TEM, proprietary 
ellagic acid activated assay; MCF, maximum clot firmness; min, minutes; PRP, platelet-rich 
plasma; ROTEM, thromboelastometry. 
 
 
 
 PRP FFP + CP 
Test Parameter Mean SD CV (%) C-α ICC Mean SD CV (%) C-α ICC 
IN-TEM CT (min) 3.3 0.3 9 0.71 0.68 4.9 0.5 10 0.97 0.92 
CFT (min) 2.6 - - - - 6.3 1.3 21 0.67 0.19 
Alpha angle (°) 66.9 3.8 6 0.49 0.49 68.7 1.6 2 0.97 0.96 
MCF (mm) 21.3 21.3 100 0.89 0.05 19.8 1.0 5 0.92 0.67 
EX-TEM CT (min) 0.6 0.0 7 0.78 0.78 0.9 0.1 12 0.87 0.35 
CFT (min) - - - - - 5.3 2.2 43 0.26 0.23 
Alpha angle (°) 69.1 3.2 5 0.90 0.42 84.4 1.2 1 0.82 0.46 
MCF (mm) 10.3 2.3 22 0.96 0.56 20.3 0.9 5 0.93 0.76 
Table 4. Within center coefficients of variation (CV) for thromboelastometry (ROTEM) assays 
(%), rounded to the nearest whole number. Abbreviations are as follows: C1-C3, Center 1 to 
Center 3; CFT, clot formation time; CT, clotting time; EX-TEM, proprietary tissue factors 
activated assay; FFP + CP, fresh frozen plasma with admixed cryoprecipitate; IN-TEM, 
proprietary ellagic acid activated assay; MCF, maximum clot firmness; PRP, platelet-rich 
plasma. Some tracings failed to reach MCF >20mm and hence values for CFT for some assays 
were not available. Coefficients of variation could not be calculated for these assays, indicated 
by (-). 
  PRP FFP + CP 
Test Parameter C1 C2 C3 C1 C2 C3 
IN-TEM CT 19 51 17 28 28 17 
CFT - - 17 22 47 61 
Alpha angle 5 24 5 17 17 11 
MCF 25 22 11 6 3 6 
EX-TEM CT 18 31 7 8 8 7 
CFT - - - 121 43 71 
Alpha angle 7 18 8 1 1 2 
MCF 15 21 12 8 6 4 
 
 
